DAC HYP, a humanized monoclonal antibody, is subcutaneous formulation of daclizumab which binds to CD25, a receptor subunit that is expressed at high levels on T cells that are abnormally activated in autoimmune conditions like MS.
Select, a phase 2b global, randomized, double-blind, placebo-controlled, one-year, dose-ranging study, comprising 600 patients, evaluated two doses of DAC HYP, 150 mg or 300 mg every four weeks.
The study met the primary endpoint which was the reduction in annualized relapse rate in patients with RRMS at one year.
The secondary endpoints were reduction in the cumulative number of new Gd+ lesions between weeks eight and 24.